We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Becton Dickinson and Company | NYSE:BDX | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 1.07 | 0.46% | 231.55 | 233.16 | 230.00 | 230.00 | 738,155 | 01:00:00 |
From Apr 2019 to Apr 2024
By Michael Dabaie
Becton, Dickinson & Co. said it received approval for a pre-market approval supplement from the U.S. Food and Drug Administration for an expanded version of its BD Onclarity HPV Assay.
The PMA supplement includes the expansion for genotype reporting beyond human papillomavirus genotypes 16, 18, and 45 to include types 31, 51, 52, 33/58, 35/39/68, and 56/59/66 genotypes.
"With this FDA approval, BD can now offer laboratories, clinicians and patients access to critical information in screening for cervical cancer in the United States and other countries recognizing the PMA supplement or CE mark," Dave Hickey, president of Integrated Diagnostic Solutions at BD, said.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
July 22, 2020 08:09 ET (12:09 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Becton Dickinson Chart |
1 Month Becton Dickinson Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
